|
1
|
Remon J, Lianes P and Martinez S: Brain
metastases from renal cell carcinoma. Should we change the current
standard? Cancer Treat Rev. 38:249–257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Salehipoor M, Khezri A, Behzad-Behbahani
A, Geramizadeh B, Rahsaz M, Aghdaei M and Afrasiabi MA: Role of
viruses in renal cell carcinoma. Saudi J Kidney Dis Transpl.
23:53–57. 2012.PubMed/NCBI
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Semenza JC, Ziogas A, Largent J, Peel D
and Anton-Culver H: Gene-environment interactions in renal cell
carcinoma. Am J Epidemiol. 153:851–859. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gu L, Li H, Chen L, Ma X, Gao Y, Li X,
Zhang Y, Fan Y and Zhang X: MicroRNAs as prognostic molecular
signatures in renal cell carcinoma: A systematic review and
meta-analysis. Oncotarget. 6:32545–32560. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sellitti DF and Doi SQ: MicroRNAs in renal
cell carcinoma. Microrna. 4:26–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Klimczak D, Pączek L, Jażdżewski K and
Kuch M: MicroRNAs: Powerful regulators and potential diagnostic
tools in cardiovascular disease. Kardiol Pol. 73:1–6. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chiang VS: Withdrawn: MicroRNAs as
potential regulators of docosahexaenoic acid benefits in
Alzheimer's disease. Nutr Neurosci. 14–Mar;2015.(Epub Ahead Of
Print). View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mennigen JA, Plagnes-Juan E,
Figueredo-Silva CA, Seiliez I, Panserat S and Skiba-Cassy S: Acute
endocrine and nutritional co-regulation of the hepatic
omy-miRNA-122b and the lipogenic gene fas in rainbow trout,
Oncorhynchus mykiss. Comp Biochem Physiol B Biochem Mol Biol.
169:16–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo Z, Wu C, Wang X, Wang C, Zhang R and
Shan B: A polymorphism at the miR-502 binding site in the
3′-untranslated region of the histone methyltransferase SET8 is
associated with hepatocellular carcinoma outcome. Int J Cancer.
131:1318–1322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Y, Cai H, Liu J, Fan H, Wang Z, Wang
Q, Shao M, Sun X, Diao J, Liu Y, et al: A miR-151 binding site
polymorphism in the 3′-untranslated region of the cyclin El gene
associated with nasopharyngeal carcinoma. Biochem Biophys Res
Commun. 432:660–665. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Couture JF, Collazo E, Brunzelle JS and
Trievel RC: Structural and functional analysis of SET8, a histone
H4 Lys-20 methyltransferase. Genes Dev. 19:1455–1465. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fang J, Feng Q, Ketel CS, Wang H, Cao R,
Xia L, Erdjument-Bromage H, Tempst P, Simon JA and Zhang Y:
Purification and functional characterization of SET8, a nucleosomal
histone H4-lysine 20-specific methyltransferase. Curr Biol.
12:1086–1099. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nishioka K, Rice JC, Sarma K,
Erdjument-Bromage H, Werner J, Wang Y, Chuikov S, Valenzuela P,
Tempst P, Steward R, et al: PR-Set7 is a nucleosome-specific
methyltransferase that modifies lysine 20 of histone H4 and is
associated with silent chromatin. Mol Cell. 9:1201–1213. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu S, Wang W, Kong X, Congdon LM, Yokomori
K, Kirschner MW and Rice JC: Dynamic regulation of the PR-Set7
histone methyltransferase is required for normal cell cycle
progression. Genes Dev. 24:2531–2542. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huen MS, Sy SM, van Deursen JM and Chen J:
Direct interaction between SET8 and proliferating cell nuclear
antigen couples H4-K20 methylation with DNA replication. J Biol
Chem. 283:11073–11077. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jørgensen S, Elvers I, Trelle MB, Menzel
T, Eskildsen M, Jensen ON, Helleday T, Helin K and Sørensen CS: The
histone methyltransferase SET8 is required for S-phase progression.
J Cell Biol. 179:1337–1345. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tardat M, Murr R, Herceg Z, Sardet C and
Julien E: PR-Set7-dependent lysine methylation ensures genome
replication and stability through S phase. J Cell Biol.
179:1413–1426. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Abbas T, Shibata E, Park J, Jha S, Karnani
N and Dutta A: CRL4 (Cdt2) regulates cell proliferation and histone
gene expression by targeting PR-Set7/Set8 for degradation. Mol
Cell. 40:9–21. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song F, Zheng H, Liu B, Wei S, Dai H,
Zhang L, Calin GA, Hao X, Wei Q, Zhang W and Chen K: An
miR-502-binding site single-nucleotide polymorphism in the
3′-untranslated region of the SET8 gene is associated with early
age of breast cancer onset. Clin Cancer Res. 15:6292–6300. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ding C, Li R, Peng J, Li S and Guo Z: A
polymorphism at the miR-502 binding site in the 3′ untranslated
region of the SET8 gene is associated with the outcome of
small-cell lung cancer. Exp Ther Med. 3:689–692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang C, Guo Z, Wu C, Li Y and Kang S: A
polymorphism at the miR-502 binding site in the 3′ untranslated
region of the SET8 gene is associated with the risk of epithelial
ovarian cancer. Cancer Genet. 205:373–376. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Singh M, Zaino RJ, Filiaci VJ and Leslie
KK: Relationship of estrogen and progesterone receptors to clinical
outcome in metastatic endometrial carcinoma: A gynecologic oncology
group study. Gynecol Oncol. 106:325–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Merritt WM, Lin YG, Han LY, Kamat AA,
Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick
AM, et al: Dicer, Drosha, and outcomes in patients with ovarian
cancer. N Engl J Med. 359:2641–2650. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen L, Qiu J, Yang C, Yang X, Chen X,
Jiang J and Luo X: Identification of a novel estrogen receptor
beta1 binding partner, inhibitor of differentiation-1, and role of
ERbeta1 in human breast cancer cells. Cancer Lett. 278:210–219.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tan B, Li Y, Zhao Q, Fan L, Wang D and Liu
Y: Inhibition of gastric cancer cell growth and invasion through
siRNA-mediated knockdown of guanine nucleotide exchange factor
Vav3. Tumour Biol. 35:1481–1488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Meng F, Wang F, Wang L, Wong SC, Cho WC
and Chan LW: MiR-30a-5p overexpression may overcome EGFR-inhibitor
resistance through regulating PI3K/AKT signaling pathway in
non-small cell lung cancer cell lines. Front Genet. 7:1972016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Süer E, Baltaci S, Burgu B, Aydoğdu Ö and
Göğüş Ç: Significance of tumor size in renal cell cancer with
perinephric fat infiltration: Is TNM staging system adequate for
predicting prognosis? Urol J. 10:774–779. 2013.PubMed/NCBI
|
|
30
|
Diao L, Su H, Wei G, Li T, Gao Y, Zhao G
and Guo Z: Prognostic value of microRNA 502 binding site SNP in the
3′-untranslated region of the SET8 gene in patients with
non-Hodgkin's lymphoma. Tumori. 100:553–558. 2014.PubMed/NCBI
|
|
31
|
Wang C, Wu J, Zhao Y and Guo Z: miR-502
medaited histone methyltransferase SET8 expression is associated
with outcome of esophageal squamous cell carcinoma. Sci Rep.
6:329212016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Landi D, Gemignani F, Naccarati A, Pardini
B, Vodicka P, Vodickova L, Novotny J, Försti A, Hemminki K, Canzian
F and Landi S: Polymorphisms within micro-RNA-binding sites and
risk of sporadic colorectal cancer. Carcinogenesis. 29:579–584.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, Wu
Y, Guo B, Shen Y, Landi D, et al: An insertion/deletion
polymorphism at miRNA-122-binding site in the interleukin-1alpha 3′
untranslated region confers risk for hepatocellular carcinoma.
Carcinogenesis. 30:2064–2069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Horikawa Y, Wood CG, Yang H, Zhao H, Ye Y,
Gu J, Lin J, Habuchi T and Wu X: Single nucleotide polymorphisms of
microRNA machinery genes modify the risk of renal cell carcinoma.
Clin Cancer Res. 14:7956–7962. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L,
Zeng Y, Miao R, Jin G, Ma H, et al: Genetic variants of miRNA
sequences and non-small cell lung cancer survival. J Clin Invest.
118:2600–2608. 2008.PubMed/NCBI
|
|
36
|
Konac E, Varol N, Yilmaz A, Menevse S and
Sozen S: DNA methyltransferase inhibitor-mediated apoptosis in the
Wnt/β-catenin signal pathway in a renal cell carcinoma cell line.
Exp Biol Med (Maywood). 238:1009–1016. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang F, Sun L, Li Q, Han X, Lei L, Zhang H
and Shang Y: SET8 promotes epithelial-mesenchymal transition and
confers TWIST dual transcriptional activities. EMBO J. 31:110–123.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
